PH30685A - Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof - Google Patents

Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof

Info

Publication number
PH30685A
PH30685A PH48985A PH48985A PH30685A PH 30685 A PH30685 A PH 30685A PH 48985 A PH48985 A PH 48985A PH 48985 A PH48985 A PH 48985A PH 30685 A PH30685 A PH 30685A
Authority
PH
Philippines
Prior art keywords
mofetil
mycrophenolate
crystalline anhydrous
intravenous formulation
crystalline
Prior art date
Application number
PH48985A
Other languages
English (en)
Inventor
Roger C Fu
De-Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Andrew R Miksztal
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of PH30685A publication Critical patent/PH30685A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PH48985A 1993-09-15 1994-09-14 Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof PH30685A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15

Publications (1)

Publication Number Publication Date
PH30685A true PH30685A (en) 1997-09-16

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
PH48985A PH30685A (en) 1993-09-15 1994-09-14 Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof

Country Status (31)

Country Link
US (2) US5543408A (pl)
EP (1) EP0724581B1 (pl)
JP (1) JP3411038B2 (pl)
KR (1) KR100349772B1 (pl)
CN (1) CN1060770C (pl)
AT (1) ATE173475T1 (pl)
AU (1) AU677435B2 (pl)
BR (1) BR9407469A (pl)
CA (1) CA2171836C (pl)
CZ (1) CZ292423B6 (pl)
DE (1) DE69414720T2 (pl)
DK (1) DK0724581T3 (pl)
ES (1) ES2123831T3 (pl)
FI (1) FI119639B (pl)
HU (1) HU217300B (pl)
IL (1) IL110970A (pl)
LT (1) LT4052B (pl)
LV (1) LV11326B (pl)
MX (1) MXPA94007099A (pl)
NO (1) NO314727B1 (pl)
NZ (1) NZ273801A (pl)
PH (1) PH30685A (pl)
PL (1) PL178522B1 (pl)
RO (2) RO118427B1 (pl)
RU (1) RU2132849C1 (pl)
SG (1) SG55006A1 (pl)
SI (1) SI9420052B (pl)
TW (1) TW370527B (pl)
UA (1) UA49797C2 (pl)
WO (1) WO1995007902A1 (pl)
ZA (1) ZA947088B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (pl) * 1998-12-09 2002-11-30 Biocon Ltd
CZ292123B6 (cs) * 2001-06-08 2003-08-13 Ivax Pharmaceuticals S.R.O. Způsob přípravy mykofenolátu mofetilu
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
ES2308226T3 (es) * 2003-09-11 2008-12-01 Sandoz Ag Proceso para la produccion de micofenolato mofetil.
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) * 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
US20060235070A1 (en) * 2005-02-08 2006-10-19 Hayden Michael R Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
PL2032521T3 (pl) 2006-06-27 2010-05-31 Sandoz Ag Nowy sposób wytwarzania soli
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
CN105452213B (zh) 2013-03-14 2017-09-22 阿尔克梅斯制药爱尔兰有限公司 富马酸酯前体药物及其在治疗多种疾病中的应用
US9168246B2 (en) * 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3836898A2 (en) 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
SU1170760A1 (ru) * 1984-02-20 1996-09-20 Ф.Ю. Рачинский Дигидробромид 2-(2-морфолиноэтилтио)бензимидазола, повышающий физическую работоспособность и ускоряющий процессы восстановления после физических нагрузок и длительного стресса
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
FR2653999A1 (fr) * 1989-11-06 1991-05-10 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
FI119639B (fi) 2009-01-30
LT4052B (en) 1996-10-25
WO1995007902A1 (en) 1995-03-23
CN1060770C (zh) 2001-01-17
IL110970A0 (en) 1994-11-28
TW370527B (en) 1999-09-21
DE69414720T2 (de) 1999-04-08
MXPA94007099A (es) 2004-01-23
SI9420052B (sl) 2004-02-29
AU7723894A (en) 1995-04-03
ES2123831T3 (es) 1999-01-16
LT96028A (en) 1996-08-26
JPH09502721A (ja) 1997-03-18
NO961075D0 (no) 1996-03-15
HU9600652D0 (en) 1996-05-28
LV11326A (lv) 1996-06-20
HUT75119A (en) 1997-04-28
LV11326B (en) 1996-10-20
KR100349772B1 (ko) 2002-12-28
FI961169A0 (fi) 1996-03-13
ATE173475T1 (de) 1998-12-15
EP0724581B1 (en) 1998-11-18
US5543408A (en) 1996-08-06
RO118427B1 (ro) 2003-05-30
SG55006A1 (en) 1998-12-21
AU677435B2 (en) 1997-04-24
US5545637A (en) 1996-08-13
BR9407469A (pt) 1996-11-12
EP0724581A1 (en) 1996-08-07
PL313480A1 (en) 1996-07-08
DE69414720D1 (de) 1998-12-24
NO961075L (no) 1996-03-15
HU217300B (hu) 1999-12-28
NZ273801A (en) 1997-10-24
DK0724581T3 (da) 1999-08-02
CZ78896A3 (en) 1996-10-16
PL178522B1 (pl) 2000-05-31
NO314727B1 (no) 2003-05-12
CA2171836C (en) 2006-11-14
SI9420052A (en) 1996-12-31
UA49797C2 (uk) 2002-10-15
ZA947088B (en) 1996-03-14
CA2171836A1 (en) 1995-03-23
IL110970A (en) 1999-01-26
RO118075B1 (ro) 2003-01-30
JP3411038B2 (ja) 2003-05-26
CZ292423B6 (cs) 2003-09-17
HK1012624A1 (en) 1999-08-06
FI961169L (fi) 1996-03-13
RU2132849C1 (ru) 1999-07-10
CN1131420A (zh) 1996-09-18

Similar Documents

Publication Publication Date Title
SG55006A1 (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
IL111365A0 (en) (r)-5-carbamoyl -8-fluoro-3-n, n-disubstituted-amino-3, 4-dihydro-2h-1- benzopyrans
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
MY100359A (en) External pharmaceutical composition.
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
GEP20032953B (en) Antitumor Agents
DE68929368D1 (de) Cephemderivate und Verfahren zu ihrer Herstellung
TW252979B (pl)
CA2063273A1 (en) Surfactant compositions and methods
ATE35812T1 (de) Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen.
WO1990003172A3 (en) Bile acids for treatment of viral infections
GEP20033054B (en) 2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
MX9600165A (es) 3-alcoxicarbonil-tiadiazinonas, proceso para su preparacion y composiciones farmaceuticas que las contienen.
EP0127389A3 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
EP0583480A4 (en) Side-effect alleviant.
EP0733364A4 (en) MIDIZINAL PREPARATION FOR THE CIRCUIT SYSTEM